$TXG

10x Genomics, Inc.

CIK:0001770787|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue	$ 151,036	$ 172,908	$ 301,879	$ 327,791
Cost of products and services revenue	38,539	47,824	83,204	97,262
Gross profit	112,497	125,084	218,675	230,529
Operating expenses:
Research and development	56,791	61,224	113,638	125,469
Selling, general and administrative	78,661	74,434	145,038	164,162
Gain on settlement	(3,400)	(40,700)	(3,400)	(49,900)
Total operating expenses	132,052	94,958	255,276	239,731
Income (loss) from operations	(19,555)	30,126	(36,601)	(9,202)
Other income (expense):
Interest income	4,797	4,271	9,811	7,957
Interest expense	0	(3)	0	(3)
Other income (expense), net	(3,887)	2,603	(4,702)	4,739
Total other income	910	6,871	5,109	12,693
Income (loss) before provision for income taxes	(18,645)	36,997	(31,492)	3,491
Provision for (benefit from) income taxes	(714)	2,459	(91)	3,311
Net income (loss)	$ (17,931)	$ 34,538	$ (31,401)	$ 180
Net income (loss) per share, basic (in dollars per share)	$ (0.14)	$ 0.28	$ (0.24)	$ 0.00
Net income (loss) per share, diluted (in dollars per share)	$ (0.14)	$ 0.28	$ (0.24)	$ 0.00
Weighted-average shares used to compute net income (loss) per share, basic (in shares)	129,984,169	123,755,409	129,050,312	123,183,924
Weighted-average shares used to compute net income (loss) per share, diluted (in shares)	129,984,169	124,509,720	129,050,312	124,258,150
Products and services revenue
Revenue	$ 149,094	$ 145,157	$ 298,990	$ 282,980
License and royalty revenue
Revenue	$ 1,942	$ 27,751	$ 2,889	$ 44,811

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net income (loss)	$ (31,401)	$ 180
Adjustments to reconcile net loss to net cash provided by operating activities:
Stock-based compensation expense	48,258	58,635
Depreciation and amortization	19,621	15,837
Non-cash lease expense	3,969	3,628
Fair value adjustments on contingent consideration	3,466	0
Asset and lease impairment charges	0	114
Deferred income taxes	(1,434)	0
Other	(616)	(926)
Changes in operating assets and liabilities:
Accounts receivable	(534)	37,917
Other receivables	32,147	(68,484)
Inventory	5,703	15,084
Prepaid expenses and other current assets	3,151	(741)
Other noncurrent assets	(11,923)	2,439
Accounts payable	8,072	3,488
Accrued compensation and other related benefits	(17,833)	(7,817)
Deferred revenue	(1,509)	(458)
Accrued contingent consideration and assumed liabilities	(613)	0
Accrued expenses and other current liabilities	(9,694)	(2,891)
Operating lease liability	(5,826)	(4,986)
Other noncurrent liabilities	90	1,040
Net cash provided by operating activities	43,094	52,059
Investing activities:
Business combination	(6,101)	0
Purchases of property and equipment	(3,185)	(3,471)
Purchases of marketable securities	(49,260)	(49,361)
Proceeds from maturities of marketable securities	50,000	50,000
Purchase of equity interest rights	(500)	0
Net cash used in investing activities	(9,046)	(2,832)
Financing activities:
Issuance of common stock from exercise of stock options	3,289	3,944
Payment of contingent consideration	(8,690)	0
Net cash provided by (used in) financing activities	(5,401)	3,944
Effect of exchange rates changes on cash and cash equivalents	(101)	474
Net increase in cash and cash equivalents	28,546	53,645
Cash and cash equivalents at beginning of period	473,966	344,067
Cash and cash equivalents at end of period	502,512	397,712
Supplemental disclosures of cash flow information:
Net cash paid for income taxes	949	1,318
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	79	301
Issuance of Class A common stock for settlement of contingent consideration	8,703	0
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 0	$ 8,307

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 502,512	$ 473,966
Marketable securities	49,521	49,443
Accounts receivable, net	47,545	47,013
Other receivables	3,084	35,480
Inventory	52,616	56,341
Prepaid expenses and other current assets	19,393	22,208
Total current assets	674,671	684,451
Property and equipment, net	215,324	226,711
Operating lease right-of-use assets	56,685	60,450
Goodwill	6,918	4,511
Intangible assets, net	61,160	62,329
Other noncurrent assets	15,308	2,913
Total assets	1,030,066	1,041,365
Current liabilities:
Accounts payable	20,694	12,733
Accrued compensation and related benefits	24,744	42,500
Accrued expenses and other current liabilities	30,377	39,971
Deferred revenue	23,610	23,902
Operating lease liabilities	12,015	10,985
Contingent consideration, current	7,069	23,363
Total current liabilities	118,509	153,454
Contingent consideration, noncurrent	2,991	1,237
Operating lease liabilities, noncurrent	66,781	73,376
Deferred revenue, noncurrent	9,683	10,501
Other noncurrent liabilities	6,556	6,471
Total liabilities	204,520	245,039
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	2,367,459	2,306,690
Accumulated deficit	(1,541,992)	(1,510,591)
Accumulated other comprehensive income	77	225
Total stockholders’ equity	825,546	796,326
Total liabilities and stockholders’ equity	$ 1,030,066	$ 1,041,365